CD4+/CD25+ cells in systemic inflammation in COPD

Department of Pneumonology and Allergology, Medical University of Warsaw, Warsaw, Poland.
Scandinavian Journal of Immunology (Impact Factor: 1.74). 01/2011; 73(1):59-65. DOI: 10.1111/j.1365-3083.2010.02474.x
Source: PubMed


The autoimmune reaction is recently suspected to play a role in the pathogenesis of chronic obstructive lung disease (COPD). As COPD is a systemic disease, the elements of an autoimmune response in circulatory system is of interest. It has been shown that regulatory T cells are important in the control of autoimmunity. There are some data on a role of adiponectin in the regulation of immune reactions. The objective of this study was to assess the elements of autoimmune reaction in the peripheral blood (PB) of patients with COPD. Twenty-eight patients with mild/moderate COPD and 20 healthy volunteers were investigated. Flow cytometry method with mixtures of monoclonal antibodies anti: CD14/CD45, CD3/CD19, CD4/CD25/CTLA4 and CD8/CD25 were used. Concentration of adiponectin was measured using ELISA method. We observed significantly lower proportion of CD4+/CD25+ as well as CD4+/CD25+ (high) cells in COPD patients than in healthy controls (15.3 versus 17.8% and 0.79 versus 1.54%, respectively, P < 0.05). The proportion of CTLA4+ cells in CD25+ cells and the mean fluorescence of CTLA4 on CD4+ cells were higher in patients than in healthy controls (10.4 versus 4.7%, P < 0.05, 189% versus 149%, non significant, respectively). We found significantly elevated concentration of adiponectin in patients when compared to healthy subjects (15.4 versus 8.5 μl/ml, P < 0.05). We found that the adiponectin/BMI ratio correlated with the decrease of FEV(1) %. The results of this study support the possible role of CD4/CD25/CTLA4 cells and adiponectin in the systemic inflammation in COPD.

Download full-text


Available from: Ryszarda Chazan, Nov 24, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The main causative agent for developing chronic obstructive pulmonary disease (COPD) is tobacco smoke. The important pathologic pathways in COPD which are related to smoking were well described. This disease affects mainly the respiratory tract. However, many data confirmed relevant systemic disturbances in course of COPD. Up to 30% of COPD cases are not attributable to smoking, however, little is known about the character of systemic inflammation in never smoking patients with COPD. The objective of this study was the evaluation of main lymphocyte subtypes currently known to play a possible role in the pathogenesis of COPD in never smokers, and their comparison with smokers with COPD, asymptomatic smokers and healthy nonsmokers. Flow cytometry method with monoclonal antibodies was used for evaluation of lymphocyte subsets: T cells, B cells, T helper and T cytotoxic, T cells with regulatory properties and the expression of Fas (CD95) on T lymphocytes. There were no differences in the proportion of T cells, B cells and CD4+ cells between the investigated groups. The proportion of CD8+ cells was significantly higher in patients with COPD than in healthy, both in non smokers and smokers group. The proportion of T lymphocytes with expression of Fas was significantly higher in never smoking patients with COPD and smokers with COPD when compared with asymptomatic smokers and nonsmokers (85% vs. 85.1% vs. 72.6% vs. 68.6% for CD4+/Fas+ and 83.2% vs. 89.1% vs. 74.3% vs. 58.8% for CD8+/Fas+ lymphocytes, respectively). The proportion of CD4+/CD25+ was lower in never smoking COPD patients than in never smoking healthy persons (14.2% vs. 19.2%). Our observation indicates important disturbances in some lymphocyte subtypes not related to smoking and their possible role in systemic inflammation in COPD.
    Central-European Journal of Immunology 01/2011; 36(4):226-232. · 0.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The co-ordinated recruitment of monocyte subpopulations, neutrophils and regulatory T-cells (Tregs) during the early stages of human acute lung inflammation remains poorly understood. We therefore performed a detailed characterisation of these lineages in the blood and lungs in a model of human acute lung inflammation. Healthy volunteers inhaled lipopolysaccharide (LPS) or saline (n=6 for each group). Blood was collected at 0, 2, 4, 6 and 8 h and bronchoscopy with bronchoalveolar lavage (BAL) performed at 8 h. Multiparameter flow cytometry was used to characterise monocyte subpopulations, neutrophils and Tregs in the blood and lung. Inhalation of LPS was associated with significant blood and BAL fluid neutrophilia. Blood populations of monocyte subpopulations and Tregs were unaltered by LPS. In contrast, LPS induced an accumulation of a pulmonary monocyte-like cell (PMLC) population, which was further subdivided into "inducible" CD14(++)CD16(-) and "resident" CD14(++)CD16(+) subsets. Inducible PMLCs were significantly increased following LPS inhalation (p=0.0046), whereas resident PMLCs were unchanged. In addition, we noted a significant decrease in Tregs in BAL fluid with LPS inhalation (p=0.027). The early stages of LPS-induced inflammation in humans is characterised by pulmonary accumulation of a novel inducible monocyte-like subpopulation, accompanied by significant changes in both neutrophil and Treg numbers.
    European Respiratory Journal 01/2012; 40(1):206-14. DOI:10.1183/09031936.00113811 · 7.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Regenerative therapy based on stem cells is applied as standard therapy in pediatric oncology. Furthermore, they are frequently used to treat immunodeficiency disorders of infants. For severe neonatal diseases, e. g. hypoxic-ischemic encephalopathy in term neonates or bronchopulmonary dysplasia in preterm infants, animal models have been established. According to some first preclinical results stem cell administration appears as a promising tool to improve the clinical outcome in high-risk infants. Provided the benefit of regenerative therapies can further be evaluated in appropriate preclinical neonate models, carefully controlled clinical trials to assess the significance of regenerative therapies, such as autologous stem cell administration, are indicated.
    Klinische Pädiatrie 06/2012; 224(4):233-40. DOI:10.1055/s-0032-1316296 · 1.06 Impact Factor
Show more